$34.97+1.49 (+4.45%)
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
Crinetics Pharmaceuticals, Inc. in the Healthcare sector is trading at $34.97. Wall Street consensus targets $83.14 (14 analysts), implying a +137.8% move over the next 12 months. The stock is currently 40% below its 52-week high of $57.99, remaining 15.9% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidat...
Crinetics Pharmaceuticals (CRNX) is back in focus after announcing that new clinical data for PALSONIFY and investigational therapy atumelnant will be presented at ENDO 2026, highlighting ongoing work in endocrine disorders. See our latest analysis for Crinetics Pharmaceuticals. The stock is trading at US$33.09 after a 1-day share price return of 1.47%. Recent momentum has softened, with the 30-day share price return down 19.78%, even as the 3-year total shareholder return is 49.73%. This...
With an analyst consensus upside of 126.9%, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) ranks among the under-the-radar stocks with massive upside for 2026. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) drew fresh analyst attention after multiple updates tied to the rollout of PALSONIFY and the company’s broader endocrine pipeline. On May 11, 2026, Oppenheimer lowered its price target on Crinetics […]
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.
Shareholders in Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) may be thrilled to learn that the analysts have just...
Crinetics Pharmaceuticals, Inc. ( NASDAQ:CRNX ) shareholders are probably feeling a little disappointed, since its...